I-Synaptogenix, Inc., inkampani ye-biopharmaceutical yesigaba somtholampilo eyakha izindlela zokwelapha ezivuselelayo ezinkingeni ze-neurodeergenerative, namuhla imemezele izinhlelo zokuthuthukisa i-Bryostatin-1 yokwelapha i-multiple sclerosis, inkomba yesithathu yomuntu ozongenela umuthi. Inkampani izosebenzisana noCleveland Clinic ngesivumelwano esisha sokubonisana.
“I-Synaptogenix iyakuthokozela ukusebenza naleli thimba lochwepheshe elaziwa emhlabeni wonke. Ukuhlolwa komtholampilo okugxile kukho kokubili ukuphepha nempumelelo kubaluleke kakhulu ukusebenzisana. Ukuthuthukisa izinhlelo zethu zokuthuthukiswa komtholampilo ngokubambisana kube yinto esigxile kuyo kulo nyaka odlule futhi kusazoqhubeka nokugxila kakhulu kuye phambili. Sijabule kakhulu ngokuthi sikwazile ukubambisana nezikhungo ezihamba phambili emhlabeni ezinhlelweni ezifana nalokhu kubambisana neCleveland Clinic ye-MS kanye nobudlelwano bethu obumenyezelwe ngaphambilini be-Fragile X ne-Nemours AI Dupont,” kusho uDkt. Alan Tuchman, oyi-CEO ye-Synaptogenix, Inc.
“I-Multiple sclerosis ijoyina i-Alzheimer’s (“AD”) nesifo se-Fragile X njengophawu lwethu lwesithathu olunenzuzo yomtholampilo engaba khona evela ku-Bryostatin-1. Ukuqedwa kwama-synapse ezigulini ze-MS, njengalezo ezilahlekile ku-AD, akuzange kubhekwane namasu ezidakamizwa atholakalayo njengamanje. Ngokusebenzisa i-synaptogenic, izindlela zokubuyisela esimweni, sikholelwa ukuthi i-Bryostatin-1 ibekwe ngendlela ehlukile ukuze iqondise ukulahlekelwa kwe-synaptic kanye nokungasebenzi kahle kwengqondo ku-MS, kanye nezinye izici zesifo ezingase zibe khona njengokuvuvukala nokuqeda amandla. Sizosebenzisana nomtholampilo wase-Cleveland ukuze siqedele umthetho olandelwayo ngokushesha ngangokunokwenzeka ngenhloso yokudlulela esivivinyweni somtholampilo ngokushesha ngemva kwalokho,” kusho uDkt. Daniel Alkon, uMongameli WeNkampani kanye Nesikhulu Esiyinhloko Sezesayensi.
